{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T02:28:04Z","timestamp":1769912884126,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T00:00:00Z","timestamp":1672617600000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"funding from Merck"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K24AI121296"],"award-info":[{"award-number":["K24AI121296"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI134637"],"award-info":[{"award-number":["R01AI134637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI48342"],"award-info":[{"award-number":["R01AI48342"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P01AI152999"],"award-info":[{"award-number":["P01AI152999"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K08AI135093"],"award-info":[{"award-number":["K08AI135093"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["K01AI148593"],"award-info":[{"award-number":["K01AI148593"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["R01AI134637"],"award-info":[{"award-number":["R01AI134637"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Ceftolozane\/tazobactam is a \u03b2-lactam\/\u03b2-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR Pseudomonas aeruginosa. This agent is approved for hospital-acquired and ventilator-associated bacterial pneumonia. However, most real-world outcome data come from small observational cohorts. Thus, we sought to evaluate the utilization of ceftolozane\/tazobactam at multiple tertiary hospitals in Houston, TX, USA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a multicentre retrospective study of patients receiving at least 48\u2005h of ceftolozane\/tazobactam therapy from January 2016 through to September 2019 at two hospital systems in Houston. Demographic, clinical and microbiological data were collected, including the infecting bacterial isolate, when available. The primary outcome was composite clinical success at hospital discharge. Secondary outcomes included in-hospital mortality and clinical disposition at 14 and 30\u2005days post ceftolozane\/tazobactam initiation. Multivariable logistic regression analysis was used to identify predictors of the primary outcome and mortality. Recovered isolates were tested for susceptibility to ceftolozane\/tazobactam and underwent WGS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 263 patients were enrolled, and composite clinical success was achieved in 185 patients (70.3%). Severity of illness was the most consistent predictor of clinical success. Combination therapy with ceftolozane\/tazobactam and another Gram-negative-active agent was associated with reduced odds of clinical success (OR 0.32, 95% CI 0.16\u20130.63). Resistance to ceftolozane\/tazobactam was noted in 15.4% of isolates available for WGS; mutations in ampC and ftsI were common but did not cluster with a particular ST.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Clinical success rate among this patient cohort treated with ceftolozane\/tazobactam was similar compared with previous experiences. Ceftolozane\/tazobactam remains an alternative agent for treatment of susceptible isolates of P. aeruginosa.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jacamr\/dlac131","type":"journal-article","created":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T08:21:34Z","timestamp":1672647694000},"source":"Crossref","is-referenced-by-count":6,"title":["Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane\/tazobactam in acute care inpatient facilities, Houston, Texas, USA"],"prefix":"10.1093","volume":"5","author":[{"given":"Truc T","family":"Tran","sequence":"first","affiliation":[{"name":"Center for Infectious Diseases Research, Houston Methodist Research Institute , Houston, TX , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolo L","family":"Cabrera","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, John T. Milliken Department of Internal Medicine, Washington University School of Medicine , St. Louis, MO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1906-359X","authenticated-orcid":false,"given":"Anne J","family":"Gonzales-Luna","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Baylor St. Luke\u2019s Medical Center, CHI St. Luke\u2019s Health , Houston, TX , USA"},{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9564-3030","authenticated-orcid":false,"given":"Travis J","family":"Carlson","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, Fred Wilson School of Pharmacy, High Point University , High Point, NC , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faris","family":"Alnezary","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX , USA"},{"name":"Department of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University , Medina , Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1518-2973","authenticated-orcid":false,"given":"William R","family":"Miller","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research, Houston Methodist Research Institute , Houston, TX , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Microbiology, Fujita Health University School of Medicine , Aichi , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An Q","family":"Dinh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Rydell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rios","sequence":"additional","affiliation":[{"name":"Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque , Bogota , Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena","family":"Diaz","sequence":"additional","affiliation":[{"name":"Molecular Genetics and Antimicrobial Resistance Unit, International Center for Microbial Genomics, Universidad El Bosque , Bogota , Colombia"},{"name":"Genomics and Resistant Microbes Group, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R) , Santiago , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2949-7818","authenticated-orcid":false,"given":"Blake M","family":"Hanson","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases, University of Texas Health Science Center School of Public Health , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose M","family":"Munita","sequence":"additional","affiliation":[{"name":"Genomics and Resistant Microbes Group, Facultad de Medicina Clinica Alemana, Universidad del Desarrollo and Millennium Initiative for Collaborative Research On Bacterial Resistance (MICROB-R) , Santiago , Chile"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Pedroza","sequence":"additional","affiliation":[{"name":"Center for Clinical Research and Evidence-Based Medicine, The University of Texas Health Science Center at Houston , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9721-263X","authenticated-orcid":false,"given":"Samuel A","family":"Shelburne","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Infection Control & Employee Health, University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8659-4238","authenticated-orcid":false,"given":"Samuel L","family":"Aitken","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, University of Texas MD Anderson Cancer Center , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2063-7503","authenticated-orcid":false,"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Baylor St. Luke\u2019s Medical Center, CHI St. Luke\u2019s Health , Houston, TX , USA"},{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Dillon","sequence":"additional","affiliation":[{"name":"Center for Observational and Real-World Evidence (CORE), Merck and Co., Inc. , Kenilworth, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Puzniak","sequence":"additional","affiliation":[{"name":"Center for Observational and Real-World Evidence (CORE), Merck and Co., Inc. , Kenilworth, NJ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar A","family":"Arias","sequence":"additional","affiliation":[{"name":"Center for Infectious Diseases Research, Houston Methodist Research Institute , Houston, TX , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Houston Methodist Hospital , Houston, TX , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,1,2]]},"reference":[{"key":"2023010208211270000_dlac131-B1","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"2023010208211270000_dlac131-B2","article-title":"2019 AR Threats Report","author":"CDC"},{"key":"2023010208211270000_dlac131-B3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1586\/erp.10.49","article-title":"Impact of multidrug-resistant Pseudomonas aeruginosa infection on patient outcomes","volume":"10","author":"Hirsch","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2023010208211270000_dlac131-B4","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1086\/379611","article-title":"Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa","volume":"37","author":"Linden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1086\/514732","article-title":"Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"28","author":"Levin","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B6","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1128\/AAC.01015-06","article-title":"Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients","volume":"51","author":"Hachem","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010208211270000_dlac131-B7","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1093\/cid\/civ717","article-title":"Colistin-associated acute kidney injury in severely ill patients: a step toward a better renal care? A prospective cohort study","volume":"61","author":"Dalfino","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B8","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1177\/1060028015593293","article-title":"Ceftolozane\/tazobactam: a new cephalosporin and \u03b2-lactamase inhibitor combination","volume":"49","author":"Sucher","year":"2015","journal-title":"Ann Pharmacother"},{"key":"2023010208211270000_dlac131-B9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/phar.1609","article-title":"Ceftolozane\/tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination","volume":"35","author":"Cho","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2023010208211270000_dlac131-B10","article-title":"Drugs","author":"FDA"},{"key":"2023010208211270000_dlac131-B11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1002\/jcph.566","article-title":"Ceftolozane\/tazobactam pharmacokinetic\/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia","volume":"56","author":"Xiao","year":"2016","journal-title":"J Clin Pharmacol"},{"key":"2023010208211270000_dlac131-B12","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2023010208211270000_dlac131-B13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B14","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2023010208211270000_dlac131-B15","article-title":"Antimicrobial-resistant phenotype definitions","author":"CDC"},{"key":"2023010208211270000_dlac131-B16","article-title":"Zerbaxa (ceftolozane and tazobactam) package insert","author":"Merck."},{"key":"2023010208211270000_dlac131-B17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023010208211270000_dlac131-B18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3389\/fmicb.2018.00685","article-title":"The versatile mutational resistome of Pseudomonas aeruginosa","volume":"9","author":"L\u00f3pez-Causap\u00e9","year":"2018","journal-title":"Front Microbiol"},{"key":"2023010208211270000_dlac131-B19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2023010208211270000_dlac131-B21","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ijantimicag.2017.11.003","article-title":"Ceftolozane\/tazobactam in the treatment of osteomyelitis and skin and soft-tissue infections due to extensively drug-resistant Pseudomonas aeruginosa: clinical and microbiological outcomes","volume":"51","author":"Dietl","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2023010208211270000_dlac131-B22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijantimicag.2017.04.001","article-title":"Use of ceftolozane\/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa","volume":"49","author":"Dinh","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2023010208211270000_dlac131-B23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s15010-018-1133-5","article-title":"Ceftolozane\/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections","volume":"46","author":"Escol\u00e0-Verg\u00e9","year":"2018","journal-title":"Infection"},{"key":"2023010208211270000_dlac131-B24","doi-asserted-by":"crossref","first-page":"e02136-16","DOI":"10.1128\/AAC.02136-16","article-title":"Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","volume":"61","author":"Cast\u00f3n","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010208211270000_dlac131-B25","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/cid\/civ411","article-title":"Ceftolozane\/tazobactam therapy of respiratory infections due to multidrug-resistant Pseudomonas aeruginosa","volume":"61","author":"Gelfand","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B26","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023010208211270000_dlac131-B27","doi-asserted-by":"crossref","first-page":"e02291-19","DOI":"10.1128\/AAC.02291-19","article-title":"Real-world experience with ceftolozane-tazobactam for multidrug-resistant Gram-negative bacterial infections","volume":"64","author":"Jorgensen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010208211270000_dlac131-B28","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1093\/jac\/dkx253","article-title":"Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods","volume":"72","author":"Schaumburg","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2023010208211270000_dlac131-B29","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1093\/cid\/ciaa381","article-title":"In vitro activity of imipenem\/relebactam and ceftolozane\/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes\u2014study for monitoring antimicrobial resistance trends, United States 2015\u20132017","volume":"72","author":"Karlowsky","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["JAC-Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/1\/dlac131\/48476838\/dlac131.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jacamr\/article-pdf\/5\/1\/dlac131\/48476838\/dlac131.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,2]],"date-time":"2023-01-02T08:21:45Z","timestamp":1672647705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jacamr\/article\/doi\/10.1093\/jacamr\/dlac131\/6966939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jacamr\/dlac131","relation":{},"ISSN":["2632-1823"],"issn-type":[{"value":"2632-1823","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,12,29]]},"article-number":"dlac131"}}